Zdrowie i gospodarka · 14/04/2005

FDA Releases Draft Guidance for Exploratory IND Studies

The Food and Drug Administration (FDA) has made available a draft guidance for industry outlining the considerations for planning exploratory investigational new drug (IND) studies in humans, which may involve limited preclinical support and fewer potential risks compared to traditional phase 1 studies.